1. Home
  2. CNF vs CUE Comparison

CNF vs CUE Comparison

Compare CNF & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNF
  • CUE
  • Stock Information
  • Founded
  • CNF 1999
  • CUE 2014
  • Country
  • CNF China
  • CUE United States
  • Employees
  • CNF N/A
  • CUE N/A
  • Industry
  • CNF Finance: Consumer Services
  • CUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • CNF Finance
  • CUE Health Care
  • Exchange
  • CNF Nasdaq
  • CUE Nasdaq
  • Market Cap
  • CNF 89.2M
  • CUE 77.3M
  • IPO Year
  • CNF 2018
  • CUE 2018
  • Fundamental
  • Price
  • CNF $0.90
  • CUE $1.06
  • Analyst Decision
  • CNF
  • CUE Strong Buy
  • Analyst Count
  • CNF 0
  • CUE 5
  • Target Price
  • CNF N/A
  • CUE $5.00
  • AVG Volume (30 Days)
  • CNF 44.7K
  • CUE 378.2K
  • Earning Date
  • CNF 12-24-2024
  • CUE 11-14-2024
  • Dividend Yield
  • CNF N/A
  • CUE N/A
  • EPS Growth
  • CNF N/A
  • CUE N/A
  • EPS
  • CNF 0.24
  • CUE N/A
  • Revenue
  • CNF $109,788,152.00
  • CUE $9,532,000.00
  • Revenue This Year
  • CNF N/A
  • CUE $105.39
  • Revenue Next Year
  • CNF $13.09
  • CUE N/A
  • P/E Ratio
  • CNF $4.00
  • CUE N/A
  • Revenue Growth
  • CNF 12.99
  • CUE 149.53
  • 52 Week Low
  • CNF $0.81
  • CUE $0.45
  • 52 Week High
  • CNF $2.84
  • CUE $3.20
  • Technical
  • Relative Strength Index (RSI)
  • CNF 41.33
  • CUE 44.25
  • Support Level
  • CNF $0.81
  • CUE $0.92
  • Resistance Level
  • CNF $1.04
  • CUE $1.23
  • Average True Range (ATR)
  • CNF 0.08
  • CUE 0.12
  • MACD
  • CNF 0.01
  • CUE -0.00
  • Stochastic Oscillator
  • CNF 34.07
  • CUE 40.00

About CNF CNFinance Holdings Limited each representing twenty (20)

CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Share on Social Networks: